Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SCN1A | P35498 | 3/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BRS3 | P32247 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502551 | 0.85 | SLC6A3 (0.42) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL14855856 | 0.81 | SLC6A3 (0.47) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL5698693 | 0.79 | SLC6A3 (0.48) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL9569998 | 0.78 | SLC6A3 (0.47) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL6983827 | 0.78 | ACHE (0.46) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL6900241 | 0.77 | SLC6A3 (0.68) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL29389473 | 0.77 | BCAT2 (0.52) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL9531321 | 0.77 | BCAT2 (0.52) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL8875151 | 0.76 | ACHE (0.48) | SLC6A3SLC6A4SCN1ASCN2ASCN3A | |
| SCHEMBL517 | 0.76 | SLC6A3 (0.50) | SLC6A3SLC6A4SCN1ASCN2ASCN3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318767-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120088788-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | SCHERING CORPORATION | 2012-04-12 | — | — | US | disclosed |
| US-8106070-B2 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100004280-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | ALBANY MOLECULAR RESEARCH, INC. | 2010-01-07 | — | — | US | disclosed |
| EP-2083822-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | Merck & Co., Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008051404-A2 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088788-A1 | SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS | BRS3, GPR119, GIPR | SLC6A3 395/4885SLC6A4 1247/4885SCN1A 1749/4885 |
| US-20100004280-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | SLC6A3 395/4885SLC6A4 1247/4885SCN1A 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.